Subcutaneous versus Intravenous Administration of Rituximab: Pharmacokinetics, CD20 Target Coverage and B-Cell Depletion in Cynomolgus Monkeys

Open Access

Peer-reviewed

Research Article

Cheng-Ping Mao,

Affiliation Discovery Inflammation, Roche Palo Alto, Palo Alto, California, United States of America
⨯
Martin R. Brovarney,

Affiliation Discovery Inflammation, Roche Palo Alto, Palo Alto, California, United States of America
⨯
Karim Dabbagh,

Affiliation Discovery Inflammation, Roche Palo Alto, Palo Alto, California, United States of America
⨯
Herbert F. Birnböck,

Affiliation Drug Metabolism and Pharmacokinetics, Roche Basel, Basel, Switzerland
⨯
Wolfgang F. Richter,

Affiliation Drug Metabolism and Pharmacokinetics, Roche Basel, Basel, Switzerland
⨯
Christopher J. Del Nagro

* E-mail: delnagro.christopher@gene.com

Affiliations Discovery Inflammation, Roche Palo Alto, Palo Alto, California, United States of America, Discovery Oncology, Genentech Incorporated, South San Francisco, California, United States of America
⨯

Reader Comments (0)

B cells
Is the Subject Area "B cells" applicable to this article?

Thanks for your feedback.
Intravenous injections
Is the Subject Area "Intravenous injections" applicable to this article?

Thanks for your feedback.
Lymph nodes
Is the Subject Area "Lymph nodes" applicable to this article?

Thanks for your feedback.
Flow cytometry
Is the Subject Area "Flow cytometry" applicable to this article?

Thanks for your feedback.
Drug administration
Is the Subject Area "Drug administration" applicable to this article?

Thanks for your feedback.
Cell staining
Is the Subject Area "Cell staining" applicable to this article?

Thanks for your feedback.
Monkeys
Is the Subject Area "Monkeys" applicable to this article?

Thanks for your feedback.
Antibody therapy
Is the Subject Area "Antibody therapy" applicable to this article?

Thanks for your feedback.